Immuron Limited executed an exclusive distribution agreement with Calmino group AB to launch PROIBS® in the United States. PROIBS® is a medical device for abdominal pain and digestive issues containing AVH200®, derived from Aloe barbadensis Mill., which has been available in European markets for over a decade. The U.S. digestive health supplement market is valued at $4.16 billion, with Immuron targeting a specific subset. This agreement expands Immuron's commercial presence following the product's launch in Australia during FY26. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.

Immuron Limited reported preliminary results for the fiscal year ended June 30, 2026, with revenue increasing 5.9% to A$7.7 million and net loss narrowing by 26.4% to A$3.8 million. Cash reserves rose significantly to A$9.0 million from A$2.8 million the prior year, supported by a large equity raise via an At-the-Market facility that increased share count to over 322 million. The company achieved key clinical milestones, including FDA approval of its IND for IMM-529 and completion of the IMM-124E trial, while signing a U.S. Department of Defense research agreement. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.

Immuron Limited filed a Form 6-K to report that CEO Steven Lydeamore presented at the Emerging Growth Conference in Melbourne on August 19, 2026. The presentation highlighted FY2026 global sales revenue of A$7.7 million, up 6% year-over-year, with strong growth in Australia and the U.S. The company announced a strategic reset to partner its clinical assets IMM-124E and IMM-529 for development and commercialization to reduce cash burn and unlock value through licensing fees and milestones. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

Immuron Limited reported FY2026 global sales revenue of A$7.7 million, a 6% increase year-over-year, with growth in Australia (up 10%) and the U.S. (up 7%). The company has shifted to a strategic partnering model for its clinical assets, IMM-124E and IMM-529, to reduce R&D expenses and cash burn. IMM-529 has received FDA IND approval for Phase 2 trials for Clostridioides difficile infection, while IMM-124E is eligible for an end-of-Phase 2 meeting with the FDA. As of December 31, 2025, the company held A$10.0 million in cash. Immuron is an Australian biopharmaceutical company developing orally delivered targeted polyclonal antibodies for infectious diseases.

Immuron Limited announced that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow in Melbourne, Australia, on July 27, 2026. The presentation is part of the company's ongoing investor engagement efforts. Immuron is a biopharmaceutical company that develops and commercializes orally delivered targeted polyclonal antibodies for treating infectious diseases.